Clinical trial
BMS-599626 in Patients With Advanced Solid Malignancies
NCT00095537 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00095537 |
|---|---|
| Title | BMS-599626 in Patients With Advanced Solid Malignancies |
| Official title | Phase I Study of BMS-599626 in Patients With Advanced Solid Malignancies, Including Malignancies That Express HER2 at the Maximum Tolerated Dose and/or Recommended Phase II Dose |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer, Metastases |
| Intervention type | Drug |
| Interventions | panHer |
| Enrollment | 60 |
| Start date | Mar 1, 2004 |
| Primary completion | May 1, 2006 |
| First posted | Nov 8, 2004 |
| Last update posted | Mar 2, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: